会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明公开
    • FLUORINATED FIBERS FOR MULTIMODAL 1H AND 19F MRI, ULTRASOUND, FLUORESCENCE DETECTION AND CONFORMATIONAL AND TEMPERATURE DETECTION BY 19F MRS
    • US20240115742A1
    • 2024-04-11
    • US18460519
    • 2023-09-01
    • New York University
    • Jin Kim MontclareDustin BrittonYoussef Zaim WadghiriFarbod Mahmoudinobar
    • A61K49/18A61K49/14A61K49/22C07K14/245G01N24/08G01N29/34G16B40/00
    • A61K49/1884A61K49/14A61K49/222C07K14/245G01N24/08G01N29/34G16B40/00B82Y40/00
    • Provided are proteins/peptides. The proteins or peptides comprise a sequence designed by the methods described herein. The proteins and peptides may have one or more trifluoroleucine (LTF, which may be referred to as TFL or LTF throughout) residues. The proteins may have or contain the following sequence:



      VX1X2X3X4X5X6X7X8X9X10X11X12X13X14X15X16X17X18X19X20X21X22X23X24X25X26X27X28X29X30X31X32X33X34X35X36X37 (SEQ ID NO:1), where X1 is A, E, D, R, H, K, Q, N, or S; X2 is A, E, N, or Q; X3 is A, V, L, I, Q, M, or LT; X4 is A, E, R, D, H, I, L, T, K, Q, N, or LT; X5 is A, F, Q, R, K, H, D, S, or E; X6 is A, L, I, or LTF; X7 is A, K, or E; X8 is A, K, E, D, R, H, Q, or N; X9 is A, T, I, L, Q, or LTF; X10 is A, L, I, or LT; X11 is A, E, D, H, P, I, L, K, Y, N, Q, R, or LT; X12 is A, Q, H, E, D, K, R, or N; X13 is A, M, I, L, Q, T, or LTF; X14 is A, L, D, E, K, I, or LTF; X15 is A, E, D, H, Y, I, L, R, K, Q, N, or Lu; X16 is A, E, or Q; X17 is A, L, M, I, V, or LTF; X18 is A, K, E, D, K, R, H, N, or Q; X19 is A, N, D, K, R, H, Q, or E; X20 is A, L, T, I, M, R, or LTF; X21 is A, N, or Q; X22 is K, A, E, I, L, M, R, H, D, Q, N, S, or LTF; X23 is A, Q, N, I, L, or LTF; X24 is A, L, I, M, T, or LT; X25 is A, H, Q, R, K, D, N, Y, I, E, L, T, or LT; X26 is A, D, E, R, K, Q, H, N, or T; X27 is A, V, I, Q, L, T, or LTF; X28 is A, R, E, D, K, H, N, Q, or T; X29 is A, H, E, R, D, K, I, L, N, Q, T, Y, or LTF; X30 is L, A, D, K, I, N, Q, or LTF; X31 is A, L, Q, I, or LTF; X32 is E, D, K, H, N, Q, A, L, R, I, Y, or LTF; X33 is A, N, Q, D, E, H, K, R, or S; X34 is Q, I, L, A, M, or LT; X35 is S, A, P, or Q; X36 is A, K, T, D, R, H, N, Q, or E; X37 is A, L, I, K, D, N, Q, R, or LTF; where at least one of X3, X4, X6, X9, X10, X11, X13, X14, X15, X16, X17, X20, X22, X23, X24, X25, X27, X29, X30, X31, X32, X34, X37 or any L is replaced with LTF. The proteins and peptides may have desirable self-assembling properties such that they form supramolecular structures (e.g., fibers or fibrils). The supramolecular structures may further gelate water such that a hydrogel is formed. The fibers and/or gels may be used to deliver drugs and/or as theranostic agents.